STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$15.34
−0.90%Margins
Gross margin
97.2%
EBITDA margin
-294.5%
EBIT margin
-309.9%
Net margin
-395.2%
FCF margin
-318.6%
174.8%
Return on equity
-92.9%
Return on assets
153.0%
Return on invested capital
0.21x
Asset turnover
-$145.2M
Cash from operations
$9.91
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026